Lanadelumab
Lanadelumab is a human monoclonal antibody against plasma kallikrein in phase III clinical trials for the prevention of acute angioedema attacks in patients with type I and type II hereditary angioedema. It was developed by Dyax.
Orphan drug designation was assigned by FDA (in 2013) and EMA (in 2015) for the treatment of hereditary angioedema. In 2015, breakthrough therapy designation was granted to lanadelumab by FDA for the same indication.
General Information
Update Date：2016-01-22
- Drug Name：
- Lanadelumab
- Research Code：
- DX-2930; X124-G01
- Trade Name：
- MOA：
- Plasma kallikrein inhibitor
- Indication：
- Hereditary angioedema (HAE)
- Status：
- Phase III (Active)
- Company：
- Dyax (Originator)
- Sales：
- ATC Code：
Biology Structure
Update Date：2016-01-22
| Type | Whole antibody |
|
| Source | Human | |
| Molecular Formula | C6468H10016N1728O2012S48 | |
| Molecular Weight | ||
| CAS No. | 1426055-14-2 | |
| Expression System |